Teriflunomide's effect on humoral response to Epstein-Barr virus and development of cortical gray matter pathology in multiple sclerosis
| Autor: | Jacqueline Durfee, Jesper Hagemeier, Deepa P. Ramasamy, Bianca Weinstock-Guttman, Murali Ramanathan, Niels Bergsland, Robert Zivadinov, Channa Kolb |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male Toluidines Hydroxybutyrates Antibodies Viral medicine.disease_cause Antiviral Agents Virus 03 medical and health sciences chemistry.chemical_compound Multiple Sclerosis Relapsing-Remitting 0302 clinical medicine Atrophy Nitriles Teriflunomide Humans Immunologic Factors Medicine Single-Blind Method In patient 030212 general & internal medicine Gray Matter Antigens Viral Cerebral Cortex biology business.industry Multiple sclerosis General Medicine Middle Aged medicine.disease Magnetic Resonance Imaging Epstein–Barr virus Titer Epstein-Barr Virus Nuclear Antigens Neurology chemistry Crotonates Immunoglobulin G Immunology Disease Progression biology.protein Capsid Proteins Female Neurology (clinical) Antibody business 030217 neurology & neurosurgery Follow-Up Studies |
| Zdroj: | Multiple Sclerosis and Related Disorders. 36:101388 |
| ISSN: | 2211-0348 |
| Popis: | Background Teriflunomide has been shown to slow cortical gray matter (GM) atrophy in patients with multiple sclerosis (MS). Previous work showed that higher levels of Epstein-Barr virus (EBV) are associated with greater development of cortical pathology in MS. Objectives To investigate whether the effect of teriflunomide on cortical volume loss in relapsing MS patients may be associated with the change in humoral response to EBV. Methods This was a prospective, observational, single-blinded, longitudinal study of 30 relapsing MS patients, who started treatment with teriflunomide, and 20 age- and sex-matched healthy controls (HCs). Subjects were assessed at baseline, 6 and 12 months with clinical, MRI and EBV examinations. MRI outcomes included percent changes in cortical, GM, deep GM and whole brain volumes. Serum samples were analyzed for IgG antibodies titers against EBV viral capsid antigen (VCA) and nuclear antigen-1 (EBNA-1). Results There were no significant differences in anti-VCA and anti-EBNA-1 IgG titers between MS patients and HC at baseline. However, over the 12-month follow-up, MS patients experienced a greater decrease in anti-EBNA-1 (−35.1, p = .003) and anti-VCA (−15.9, p = .05) IgG titers, whereas no significant changes were observed in HCs (−3.7 and −1.6, respectively). MS patients who showed the highest decrease in anti-EBV VCA and EBNA-1 IgG titers from baseline to follow-up, developed less cortical (p Conclusions Teriflunomide's effect on slowing cortical and GM volume loss may be mediated by its effect on altering humoral response to EBV. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect